FRIENDSWOOD, Texas, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has been included in the inaugural 2025 America’s Greatest Companies list, published by Newsweek. The ranking honors 650 U.S. companies demonstrating strong performance across four key pillars: financial strength, workforce dedication, innovation, and commitment to environmental sustainability and corporate ethics. “This recognition from ...

Summary of Castle Biosciences Conference Call Company Overview - Castle Biosciences is a diagnostic services company focused on guiding patient care and improving outcomes through a portfolio of tests, including MyPath Melanoma, DecisionDx-Melanoma, DecisionDx-SCC, and TissueCypher for Barrett's esophagus [3][4][5] Key Products and Services - **MyPath Melanoma**: A genomic test for identifying or ruling out melanoma in indeterminate biopsy samples [3] - **DecisionDx-Melanoma and DecisionDx-SCC**: Tests providing risk scores for skin cancers, aiding in treatment decisions [4] - **TissueCypher**: A spatial protein test for assessing the risk of Barrett's esophagus progressing to esophageal cancer, with a five-year mortality rate of 85% for esophageal cancer [4] - **ESOPredict**: Recently acquired test with similar utility to TissueCypher, aimed at identifying Barrett's esophagus [5] - **Atopic Dermatitis Program**: Collaboration with Cybase to identify flares of atopic dermatitis [3][5] Financial Performance - The company reported strong growth in its portfolio and maintained a high gross margin, with approximately $275 million in cash at year-end, positioning it well for future opportunities [5][6] Market Penetration and Growth Potential - Current testing penetration for melanoma is estimated at 30-31% of suitable patients, with significant room for growth as melanoma is underreported [9][10] - Approximately 55-60% of eligible clinicians have used Castle's dermatology tests, indicating potential for increased adoption [10] - Long-term growth is expected to be in the high single digits, with seasonal variations impacting volume [13][15] Reimbursement and Coverage - The company received acceptance for reconsideration requests for its squamous cell carcinoma test from Medicare contractors, which is seen as a positive administrative milestone [20][21] - Significant publications supporting the clinical utility of the SCC test suggest potential cost savings for Medicare, which could influence future coverage decisions [23][24] Strategic Direction - Castle Biosciences aims to identify clinical questions that lack adequate answers and develop tests to address these needs, with a focus on both dermatology and gastroenterology [26][30] - The company has expanded its sales force to enhance market penetration, particularly in the GI space, and is focused on maintaining strong relationships with physicians [36][39] Future Outlook - The company anticipates continued strong growth for its tests, particularly TissueCypher, with an expanding patient pool and positive physician response [40][41] - There is an ongoing emphasis on R&D to enhance existing tests and develop new ones, ensuring the company remains competitive in the diagnostic testing market [7][34] Additional Insights - The company has made strategic acquisitions, such as Previse, to enhance its product offerings and address unmet clinical needs [31][32] - The focus on automation and efficiency in lab processes has contributed to maintaining attractive gross margins despite varying profitability across different test types [34][35]

In the study, TissueCypher identified that 15% of patients with non-dysplastic Barrett's esophagus (NDBE) had a probability of progression that was similar to, or exceeded, progression rates associated with low-grade dysplasia (LGD); current guidelines recommend prompt intervention for LGD to prevent disease progressionFRIENDSWOOD, Texas, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced th ...

Group 1 - The core consideration for companies in molecular diagnostics is their ability to translate complex scientific concepts into commercially viable businesses [1] - Nabeel Bukhari combines legal expertise in corporate law with self-taught financial analysis skills, providing a unique perspective on business dynamics [2] - His insights have been published in respected platforms and featured in well-known publications, enhancing the understanding of financial analysis in the context of corporate law [2] Group 2 - There is no indication of any stock or derivative positions held by the analyst in the companies mentioned, ensuring an unbiased perspective [3] - The article expresses personal opinions and does not involve compensation from any company mentioned, reinforcing the independence of the analysis [3] - Seeking Alpha clarifies that past performance does not guarantee future results and that the views expressed may not reflect the platform's overall stance [4]

Core Insights - The DecisionDx-SCC test significantly outperforms current staging systems in predicting local recurrence and metastasis for NCCN high-risk patients with cutaneous squamous cell carcinoma (SCC) [1][3][4] - The test provides individualized risk predictions that align with treatment decision-making for adjuvant radiation therapy (ART) and surveillance imaging [2][5] Study Findings - The first study demonstrates that DecisionDx-SCC predicts local recurrence in high-risk patients post-Mohs resection, adding a third validated use to the test [2][4] - The second study confirms that clinicians utilize test results to guide recommendations for ART and surveillance imaging based on individual patient risk [2][5] Clinical Implications - DecisionDx-SCC effectively stratifies risk among 414 NCCN high-risk SCC patients, showing three-year local recurrence-free survival rates of 95.3% for low risk (Class 1), 85.5% for higher risk (Class 2A), and 71.4% for highest risk (Class 2B) [4] - The test's predictive accuracy improves when combined with established clinicopathologic factors, enhancing risk stratification beyond traditional staging systems [4][5] Clinician Insights - A survey of 244 clinicians revealed that most recommend ART for patients with a ≥20% risk of local recurrence or metastasis and surveillance imaging for those with a ≥10% risk of metastasis [4][5] - Clinicians reported that Class 2B test results are among the most critical factors in management decisions for ART [5] Company Overview - Castle Biosciences, Inc. focuses on innovative diagnostic tests that guide patient care, with a portfolio that includes tests for skin cancers and other diseases with high clinical need [7][8] - The company aims to transform disease management by prioritizing the needs of patients, clinicians, employees, and investors [7]

Company Overview - Castle Biosciences, Inc. is scheduled to present a company overview at Baird's 2025 Global Healthcare Conference on September 10, 2025, at 10:15 a.m. Eastern time [1] - The company is a leading diagnostics firm focused on improving health through innovative tests that guide patient care [4] Upcoming Events - A live audio webcast of the company's presentation will be available on its website, with a replay accessible after the live broadcast [2] - Castle will participate in one-on-one investor meetings during the Wells Fargo 20th Annual Healthcare Conference on September 4, 2025, and the 9th Annual Lake Street Best Ideas Growth Conference on September 11, 2025 [3] Product Portfolio - Castle's current portfolio includes tests for skin cancers, Barrett's esophagus, and uveal melanoma [5] - The company is engaged in research and development for additional tests, including one aimed at guiding systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment [5]

Summary of Castle Biosciences (CSTL) FY Conference Call - August 12, 2025 Company Overview - Castle Biosciences specializes in dermatologic and gastrointestinal (GI) cancer tests, including DecisionDx Melanoma and TissueCypher for GI cancer [1][2] Key Financial Performance - In Q2, Castle Biosciences reported a **33% year-over-year growth in volume** and **23% revenue growth**, totaling **$276 million** in cash at the end of the quarter and generating **$21 million** in operating cash flow [4][49] Core Products and Market Penetration - **TissueCypher**: Achieved nearly **100% year-over-year growth in volume**. Current market penetration is about **10%** for patients and higher for physicians, indicating significant growth potential [6][10] - **DecisionDx Melanoma**: Expected to grow at **high single digits** year-over-year, with a strong performance in Q2 showing **4% growth** year-over-year [32][34] Strategic Initiatives - Expansion of the sales force for the GI business, with plans to increase staffing to better serve approximately **10,000 gastroenterologists** [11] - Acquisition of **Previse**, which offers the complementary **ESA Predict** test, aimed at enhancing the GI cancer testing portfolio [13][15] Pipeline Developments - Development of a new test for **atopic dermatitis**, targeting a market of approximately **24 million** diagnosed patients in the U.S., with **7.4 million** in the moderate to severe category [21][22] - The test aims to predict responses to systemic therapies, with a focus on achieving a **90% clearance** in lesions [27][29] Regulatory and Reimbursement Landscape - **DecisionDx Melanoma** received a breakthrough device designation from the FDA, which could lead to improved reimbursement and market access [35][38] - Ongoing efforts to secure Medicare coverage for **SooDx SCC**, with a valid reconsideration request submitted to both Novitas and MolDX [40][44] Investor Insights - Castle Biosciences has demonstrated a **CAGR of 52%** since going public in July 2019, positioning itself as a strong performer in the diagnostic space [49][50] - The company is well-positioned for near-term and mid-term growth, with multiple product lines showing promise and a healthy cash flow [50] Conclusion - Castle Biosciences is focusing on expanding its market presence in both dermatologic and GI cancer testing, with strong financial performance and strategic acquisitions supporting its growth trajectory. The company is also navigating regulatory challenges while preparing for new product launches in the near future [52]

Castle Biosciences (CSTL 4.37%), a developer of diagnostic tests supporting personalized treatment decisions in dermatology and gastroenterology, reported its second quarter 2025 results on August 4, 2025. The company significantly outperformed Wall Street expectations in Q2 2025, with GAAP EPS of $0.15 and non-GAAP revenue of $86.2 million, both exceeding analyst estimates. GAAP earnings per share reached $0.15, well above the consensus estimate of -$0.53. Non-GAAP revenue was $86.2 million, surpassing the ...

分组1 - Castle Biosciences, Inc. reported quarterly earnings of $0.15 per share, exceeding the Zacks Consensus Estimate of a loss of $0.51 per share, representing an earnings surprise of +129.41% [1] - The company posted revenues of $86.19 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 16.64%, although this is a slight decrease from year-ago revenues of $87 million [2] - Castle Biosciences has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock has underperformed the market, losing about 45% since the beginning of the year, while the S&P 500 has gained 6.1% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.63 on revenues of $66.56 million, and -$2.29 on revenues of $295.13 million for the current fiscal year [7] 分组3 - The Zacks Industry Rank indicates that the Medical - Biomedical and Genetics sector is currently in the bottom 43% of over 250 Zacks industries, suggesting potential underperformance compared to the top 50% of ranked industries [8] - The estimate revisions trend for Castle Biosciences was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6]

Castle Biosciences (CSTL) Q2 2025 Earnings Call August 04, 2025 04:30 PM ET Company ParticipantsCamilla Zuckero - VP - IR & Corporate AffairsDerek Maetzold - Founder, CEO, President & DirectorFrank Stokes - CFOPuneet Souda - Senior MD - Life Science Tools & DiagnosticsConference Call ParticipantsThomas Flaten - Senior Research AnalystMason Carrico - Research AnalystMark Massaro - MD & Senior Equity Research AnalystKyle Mikson - Managing Director & Senior Research AnalystSubbu Nambi - MD - Senior AnalystCath ...